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Abstract
Aims: The Stent Thrombosis In Belgium (STIB) trial aimed to determine whether assessing platelet reactivity 
(PR) in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention 
(PCI) could predict the risk of ischaemic complications and adverse clinical events up to 30 days post PCI.
Methods and results: PR before intervention was determined in 891 patients undergoing PCI for stable 
angina pectoris. Twelve to 24 hours before PCI, all patients received a 600 mg clopidogrel dose followed by 
75 mg daily, and 500 mg of aspirin followed by 80-100 mg daily. Residual PR was assessed by VerifyNow 
point-of-care aspirin and P2Y12 assay before PCI. “Non-responders” to antiplatelet therapy were defined as 
aspirin reaction unit (ARU) >550 and as P2Y12 reaction unit (PRU) >230. The endpoint of the study was the 
composite of periprocedural myonecrosis, stent thrombosis, non-fatal myocardial infarction (MI), stroke and 
death at 30 days in patients with or without high PR. The endpoint was observed in 180 patients: four deaths, 
one stroke, 11 Q-wave MI, three non-Q-wave MI and 161 periprocedural myonecroses. At multivariate analy-
sis, the endpoint was predicted by total stent length (OR: 1.020), GFR <60 ml/min (OR: 1.87), history of PCI 
(OR: 0.58), white blood cell count (OR: 1.95) and diabetes (OR: 1.83). No significant association was found 
between residual PR and the primary endpoint or any of its components.
Conclusions: PR measured before PCI in stable patients undergoing elective PCI who are preloaded with 
500 mg of aspirin and 600 mg of clopidogrel is not predictive of periprocedural myocardial injury or adverse 



















High platelet reactivity (PR) to clopidogrel or aspirin is associ-
ated with an increased risk of stent thrombosis and is a predictor 
of recurrent ischaemic events in patients with acute coronary syn-
drome (ACS)1,2. Conversely, a high loading dose of clopidogrel 
and/or optimal platelet inhibition significantly reduces ischaemic 
and cardiovascular complications in patients with ACS undergoing 
percutaneous coronary intervention (PCI)3-5. There is an unambigu-
ous clinical benefit achieved with a 600 mg loading dose of clopi-
dogrel against ischaemic complications following PCI performed 
in individuals presenting with an ACS6,7. Additionally, a seven-day 
double dose clopidogrel maintenance therapy after PCI offers a sig-
nificant advantage over a single (75 mg) maintenance dose with 
respect to cardiovascular events and stent thrombosis, but carries 
an increased risk of bleeding8.
The efficacy of clopidogrel is, however, influenced by the 
large interindividual variability in the concentration of the active 
metabolite9,10, and the optimal dose for clopidogrel following per-
cutaneous coronary intervention is debated. To overcome this 
problem, tests for diagnosing platelet responsiveness have been 
developed. Notably, on-treatment platelet reactivity can be eval-
uated by a point-of-care assay (VerifyNow®; Accumetrics Inc., 
San Diego, CA, USA). This test has been proposed to identify 
patients who are “non-responders” to antiplatelet treatment in 
order to adjust the dosage accurately. This strategy appears to be 
effective in patients who experience acute stent thrombosis as 
well as in patients undergoing PCI for acute coronary syndromes. 
Consequently, assessment of platelet reactivity to guide and tai-
lor antiplatelet treatment in interventional procedures for patients 
with unstable angina or non-ST myocardial infarction is a class 
IIb recommendation11.
In contrast to ACS trials, the use of high-dose clopidogrel or 
the use of prasugrel compared with standard dose clopidogrel did 
not reduce the incidence of ischaemic cardiovascular events at 
six months in patients with high on-treatment PR after PCI for 
stable coronary artery disease12,13. These findings suggest that, in 
patients referred for the treatment of stable coronary artery dis-
ease, late thrombotic risk is not altered by a strategy aiming to 
reduce PR further. Nevertheless, the results of the GRAVITAS 
trial showed that patients achieving an on-clopidogrel reactivity 
<208 P2Y12 reaction units (PRU) after PCI had a lower risk for 
late cardiovascular events14. However, this observation may have 
been influenced by other factors related to the complexity of the 
PCI performed. 
Whether the risk of ischaemic complications and unwanted clini-
cal events during 30 days post PCI in stable patients is also deter-
mined by the level of PR at the time of PCI is as yet uncertain. We 
therefore designed the Stent Thrombosis In Belgium (STIB) trial 
to determine whether patient PR assessment before intervention, 
after uniformly loading patients with a standardised dual antiplate-
let therapy, could determine the risk of ischaemic complications 
and unwanted clinical events during 30 days following PCI in sta-
ble patients.
Methods
The Stent Thrombosis In Belgium (STIB) trial was a prospective, 
multicentre study in patients with stable coronary artery disease eli-
gible for PCI of one or two vessels. Its objective was to study the 
impact of PR to clopidogrel and aspirin on adverse clinical events 
potentially occurring in-hospital and up to 30 days post PCI.
STUDY DESIGN
At five medical centres patients with stable coronary artery disease 
planned for PCI received a clopidogrel loading dose of 600 mg and 
an aspirin loading dose of 500 mg, 12 to 24 hours before PCI. 
Following intervention, a daily dose of clopidogrel (75 mg) and 
aspirin (80 to 100 mg) was given. All PCIs were performed accord-
ing to current standard guidelines. The type of stent was left at the 
discretion of the operator. Patients received unfractionated heparin 
70 IU/kg during the procedure. Patients with concomitant use of 
antithrombotic drugs other than aspirin or clopidogrel or with the 
need for glycoprotein IIb/IIIa inhibitors were excluded. 
PR was measured in the catheterisation laboratory before PCI by 
the VerifyNow point-of-care test with the P2Y12 cartridge to test 
the degree of platelet inhibition to clopidogrel and with the aspirin 
cartridge to assess the degree of platelet inhibition to aspirin 
(Accumetrics Inc.)15. Measures of the antiplatelet effect of clopi-
dogrel are expressed as P2Y12 reaction units (PRU). High PR has 
been defined in numerous studies as >230 PRU12,16. Measures of the 
antiplatelet effect of aspirin are expressed as aspirin reaction units 
(ARU). ARU values less than 550 indicate that platelets are inhib-
ited by aspirin17. Operators were blinded to the PRU and ARU 
measurements.
In all patients blood samples were drawn before and at eight and 
24 hours for creatine kinase-myocardial band (CK-MB) and tro-
ponins (TnT or TnI). Hs-troponin assays were not used. Laboratory 
data including haematocrit, platelet count, fibrinogen, creatinine, 
glycated haemoglobin A1C and C-reactive protein were also 
obtained before PCI.
In-hospital and one-month clinical events were collected for all 
patients and recorded on a standardised electronic clinical case 
record (modified BWGIC/CARDS database of the ESC EuroHeart 
Survey, Heart House, Nice, France). An independent clinical events 
committee (JB, MC) which had access to the database reviewed and 
adjudicated all suspected primary endpoints every three months. 
Each patient provided informed consent to the study. The study 
was supported by an unrestricted grant from BIOTRONIK SE & 
Co. KG, Berlin, Germany. The trial was approved by the institu-
tional ethics committee of each participating institution and com-
plied with the Declaration of Helsinki. It was not registered.
CLINICAL ENDPOINTS 
The primary endpoint of the STIB study was the composite of 
30-day periprocedural myonecrosis, stent thrombosis, non-fatal 
myocardial infarction, stroke and death in patients with or with-
out high PR (“non-responders” or “responders”). Secondary end-
points included in-hospital major bleeding complications, subgroup 









analysis of patients with in-hospital myonecrosis unrelated to pro-
cedural complications and stent thrombosis.
All deaths were considered cardiovascular unless an unequivocal 
non-cardiovascular cause could be established. Myocardial infarc-
tion (MI) was defined as a post-procedural increase of a cardiac 
biomarker (Tn) >3x the upper reference limit (URL)18. The pres-
ence of new pathological Q-waves in two or more contiguous ECG 
leads was referred to as Q-wave MI, while myonecrosis was defined 
as any Tn elevation >3x URL without persistent ECG changes. 
Stroke included occurrence of cerebral infarction (ischaemic 
stroke) and intracerebral/subarachnoïdal haemorrhage (haemor-
rhagic stroke). Definite or probable stent thrombosis, according to 
the Academic Research Consortium definitions19, was a secondary 
endpoint unless it occurred without death or myocardial infarction. 
Major bleeding (haemorrhagic) complications included haematoma 
requiring transfusion or surgical repair, intracerebral or subarach-
noid haemorrhage (haemorrhagic stroke) and any bleeding event 
associated with a haemoglobin drop >5 g/dL or requiring transfu-
sion or surgical repair (e.g., retroperitoneal bleed, gastrointestinal 
bleed, access-site bleed). 
Troponin elevation above 3x URL after PCI in survivors without 
Q-wave MI, acute stent thrombosis or stroke (patients with proce-
dural myonecrosis) was further characterised by the data safety 
monitoring board committee as: 1) related to an obvious procedural 
complication such as side branch occlusion, need for urgent CABG, 
rotablator use, residual Type C/D coronary dissection or cardiac 
arrest during PCI; 2) associated with slow flow in the main vessel 
or side branch, or residual thrombus post PCI; or 3) without identi-
fiable cause of Tn elevation.
STATISTICAL ANALYSIS
The sample size was calculated assuming a 21% incidence of the 
primary endpoint at 30 days20. We hypothesised a 30% reduction in 
the incidence of endpoints in patients with low PR compared with 
patients with a residual high degree of PR21. A sample size of at 
least 860 patients would be needed to fulfil these assumptions with 
a statistical power of 0.90 to detect the hypothesised effect size with 
a two-sided p-value <0.05.
Continuous variables are presented as mean value±standard 
deviation. Categorical data are reported as frequencies and per-
centages. Differences in continuous variables were compared by 
one-way analysis of variance. Comparisons of categorical varia-
bles were tested by the χ2 test or Fisher’s exact test, as appropriate. 
Multivariate stepwise logistic regression was used to identify 
independent predictors of the occurrence of the composite end-
point in the 30-day period. The variables (demographic, clinical, 
procedural, and laboratory) entered in the model were selected 
using stepwise regression analysis with an entry criterion of 
p<0.10. Odds ratio (OR) and 95% confidence intervals (CI) were 
calculated. All probability values reported are two-sided, and 
a value of p<0.05 was considered to be significant. All analysis 
was performed with SPSS version 13.0 software (SPSS Inc., 
Chicago, IL, USA).
Results
Between March 2008 and October 2010, 923 consecutive patients were 
screened with platelet function testing from five sites in Belgium, 
among 3,671 patients with stable CAD treated by PCI. Thirty-two 
patients were excluded because of protocol violation (abnormal Tn 
value before PCI in 28 and the need for glycoprotein IIb/IIIa inhibitors 
in four). Among the 891 eligible patients, PRU was obtained in 882 and 
ARU in 852 patients. Both PRU and ARU values were available in 848 
patients. Baseline characteristics of the patients are presented in Table 1.
PHARMACODYNAMIC OUTCOMES
The cumulative distribution of the platelet function measured 







0 200 300100 400 500 600 700 800












–100 200 3000 100 400 500 600 700 800








Figure 1. Cumulative distribution of the PR before PCI following 
aspirin (500 mg) and clopidogrel (600 mg) administration. 
A) Aspirin reactivity is shown and expressed in aspirin reaction units 
(ARU). Values above 550 indicate high residual PR to aspirin or 
non-responders12. B) Clopidogrel reactivity is shown and expressed 
in P2Y12 reaction units (PRU). Values above 230 indicate high 
residual PR to clopidogrel or non-responders9,11.
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Figure 2. Plots of individual data of aspirin reaction units (ARU) 
in the y-axis and P2Y12 reaction units (PRU) in the x-axis. ARU 
values above 550 indicate high residual activity to aspirin and 
PRU values above 230 indicate high residual activity to 
clopidogrel (Figure 1). Only 4% of the patients are non-responders 
to aspirin and clopidogrel and 47.3% are responders to both 
antiplatelet agents.
(aspirin non-responders) represented 6.7% of the population, 
while high PR after clopidogrel (clopidogrel non-responders) was 
observed in 50.2%. Figure 2 illustrates response to both aspirin 
and clopidogrel in 848 patients in whom both measurements were 
obtained. Only 34 patients (4%) were non-responders to both 
aspirin and clopidogrel. Twenty-three patients (2.7%) were resist-
ant to aspirin but responded to clopidogrel. Conversely, 60% of 
aspirin non-responders still had a high PR following a 600 mg 
loading dose of clopidogrel. 
Table 1. Baseline clinical and procedural characteristics of the 
study patients.
Characteristics Mean or n ±SD or (%)
Demographic data
Age mean (SD), yrs 66.2 10.8
Men 676 (75.9)
BMI mean (SD), kg/m2 28.5 0.9
Diabetes mellitus 221 (24.8)
Hypertension 577 (64.8)
Hyperlipidaemia 647 (72.6)
Current smoker 202 (22.7)
Myocardial infarction 230 (25.8)
PCI 358 (40.2)
CABG 94 (10.5)





Angiotensin receptor blocker 315 (35.4)
Statin 601 (67.5)
Coronary anatomy
LVEF <50% 117 (13.1)
1 VD 444 (49.8)
2 VD 301 (33.8)
3 VD 145 (16.4)
Procedural data
1 Vx PCI 753 (84.5)
2 Vx PCI 133 (14.9)







Direct stenting 329 (36.9)
Stent length (mm) 29.6 18
Biology before PCI
ARU mean (SD) 433.89 71.02
PRU mean (SD) 221.36 102.40
Haemoglobin (g/dL) mean (SD) 13.93 1.61
Haematocrit (%) mean (SD) 41.12 4.29
Platelet (x1,000) (/microL) mean (SD) 246.02 75.80
Fibrinogen (mg/dL) mean (SD) 361.24 102.89
uCRP (mg/dL) mean (SD) 2.87 6.02
HbA1c (%) mean (SD) 6.18 0.96
In order to address the influence of demographic and biological 
variables on the PRU value, the distribution of these variables 
across PRU quartiles was evaluated (Table 2). High reactivity 
after clopidogrel treatment was associated with increasing age 
and increased body mass index, poor diabetic control, low haemo-
globin level and higher fibrinogen values at admission.
ENDPOINTS
The primary endpoint occurred in 180 patients (20%) and was 
driven by in-hospital events in 173 patients (Table 3). Four 
patients died. In one case, death was related to a cardiogenic 
shock which followed an acute anterior MI complicating a PCI of 
an ostial circumflex artery (ARU: 419, PRU: 223). One patient 
experienced a subacute stent thrombosis complicated by 
ST-elevation MI and died five days post PCI (ARU: 473, PRU: 
386). Two other patients died suddenly at home (ARU/PRU: 
383/114 and 473/67, respectively). Another patient experienced 
a subacute stent thrombosis and a non-Q-wave MI at day 15 
(ARU: 403, PRU: 124). New Q-wave MI related to the procedure 
was observed in 10 cases. An additional Q-wave MI and two 









non-Q-wave MI unrelated to the treated vessel occurred during 
follow-up. According to ARC definitions, four patients suffered 
a definite or probable stent thrombosis. Post-procedural elevation 
of troponin >3x URL (myonecrosis) was diagnosed in 161 cases. 
The incidence of the primary endpoint was not related to treat-
ment reactivity on either aspirin or clopidogrel (Figure 3). 
CLINICAL, PROCEDURAL AND LESION CHARACTERISTICS 
AND CLINICAL OUTCOME
The association of patients’ demographic, clinical, biological and 
procedural characteristics with clinical outcomes was studied. On 
Table 2. Distribution of demographic and biological variables across PRU quartiles.
1st quartile 2nd quartile 3rd quartile 4th quartile p-value
PRU 84±43 190±24 262±19 346±41
Age (yrs) 63.7 65 66.2 69.2 0.0001
BMI (kg/m2) 27.08 27.26 28.34 28.22 0.009
HbA1c (%) 5.97 6.06 6.28 6.26 0.026
GRF <60 ml/min, n (%) 37 (16.7) 47 (21.2) 37 (16.7) 35 (15.8) NS
Hb (g/dL) 14.3 14.3 13.9 13.4 0.0001
Fibrinogen (ml/dL) 351 347 354 381 0.013
Tn >3x URL, n (%) 43 (19.4) 46 (21.6) 39 (18.2) 43 (20.6) NS







Death 1 (0.1%) 4° (0.4%)
Stroke 1 (0.1%) 1 (0.1%)
Q-wave MI 10 (1.1%) 11 (1.2%)
Non-Q-wave MI – 3* (0.3%)
Myonecrosis (Tn >3x URL) 161 (18.1%) 161 (18.1%)
°1 subacute stent thrombosis at day 5; *1 subacute stent thrombosis at 
day 14; n: number of patients
univariate analysis, neither ARU nor PRU was associated with pri-
mary endpoints. In the multivariate model, five variables emerged 
as independent predictors: total stent length (OR: 1.020; 95% CI: 
1.009-1.031, p<0.0001), GFR <60 ml/min (OR: 1.87; 95% CI: 
1.19-2.94, p=0.007), history of PCI (OR: 0.58; 95% CI: 0.38-0.88, 
p=0.008), white blood cell count (OR: 1.033; 95% CI: 1.001-1.052, 
p=0.013) and diabetes (OR: 1.83; 95% CI: 1.12-3.00, p=0.016).
PROCEDURAL MYONECROSIS, PROCEDURAL EVENTS AND 
PLATELET REACTIVITY
After exclusion of 12 patients who suffered in-hospital death, stroke, 
or Q-wave MI, and of 32 patients without determination of troponin 
and PRU, the cohort of patients was classified into four groups 
according to the assessment done by the data safety monitoring 
board. Group 1 comprised 54 patients in whom Tn elevation was 
related to an identifiable procedural complication such as side branch 
occlusion, need for urgent CABG, rotablator use, residual Type C/D 
coronary dissection or cardiac arrest during PCI. Group 2 comprised 
22 patients with slow flow in the main vessel or side branch, or resid-
ual thrombus post PCI. Group 3 comprised 118 patients without iden-
tifiable cause of Tn elevation. Group 4 comprised 653 patients 
without abnormal troponin elevation post PCI. Mean PRU values in 
each group were 220.6±101.8, 227.6±103.9, 224.0±109.3, 
206.33±97.3 and the percentage of patients with high residual plate-
let activity to clopidogrel was 50.4%, 50.8%, 40.9% and 44.4% in 
Group 1, Group 2, Group 3 and Group 4, respectively (p: NS).
SAFETY ENDPOINT
Major bleeding occurred in six patients: access-site bleeding in three, 
haemorrhagic stroke in two and gastrointestinal bleeding in one. Five 
of these patients had PRU values >230 (clopidogrel non-responders). 
At one-month follow-up, the rate of drug discontinuation was 4.4% 
for aspirin and 13.4% for clopidogrel. Only six patients interrupted 
both drugs. No patient had to stop antiplatelet treatment because of 
bleeding or haemorrhagic complications, and reasons for clopidogrel 
discontinuation were not reported. Among patients who stopped 
clopidogrel, one had a repeat PCI of a non-culprit vessel at 30 days. 
Discussion
In this prospective multicentre study, we addressed the value of PR 



















ARU <550 (n=795) ARU >550 (n=57) PRU <230 (n=439) PRU >230 (n=443)
Figure 3.  Frequency of primary endpoint (death, stroke, stent 
thrombosis, non-fatal myocardial infarction and troponin elevation 
>3x URL) among patients with or without high on-treatment PR.  
High PR on aspirin (ARU >550: non-responder to aspirin) or on 
clopidogrel (PRU >230: non-responder to clopidogrel) did not result 
in a significant increased risk of ischaemic events (p: NS).
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stable angina pectoris and who were pretreated according to the 
current standard with aspirin 500 mg plus clopidogrel 600 mg at 
least 12 hours before the procedure. A high PR as assessed before 
intervention by a point-of-care assay does not predict procedural 
ischaemic clinical events or a worse clinical outcome up to one 
month. Reactivity to clopidogrel shows a wide interindividual vari-
ability yielding 50.2% non-responders to clopidogrel, while PR to 
aspirin is more predictable with only 6.7% non-responders to aspi-
rin according to suggested definitions12,16,17. We also found that 
response to clopidogrel diminishes with advancing age and increas-
ing body mass index. Glycaemic control, haemoglobin and fibrino-
gen are also linked to clopidogrel resistance.
Results of the ARMYDA-PRO study indicate that high pre-PCI 
PR measured by the VerifyNow assay might predict 30-day events 
in stable patients loaded with 600 mg clopidogrel. In this study, the 
primary endpoint was more frequent in patients with preprocedural 
PRU levels in the fourth quartile versus those in the first quartile, 
and this was essentially due to periprocedural MI22. There was, 
however, a substantial overlap in PRU values between groups and 
no difference was found when troponin elevation was used to define 
periprocedural MI. Hochholzer et al21 showed that the incidence of 
ischaemic events increased gradually from the first to the fourth 
quartile (p=0.03) among stable patients undergoing stent implanta-
tion. However, the low incidence of events in 15 out of 802 patients 
reduces the power of this observation, and quartiles of platelet 
aggregation were not associated with periprocedural elevations in 
troponin. Our study extends and clarifies these observations. First, 
we confirm the very low incidence of major clinical events at 30 
days in stable patients undergoing PCI with the current standard of 
care. Second, we prove that the variability of response to clopi-
dogrel is large and not associated with periprocedural myonecrosis, 
even when analysis is performed according to quartiles of platelet 
aggregation (Table 2). 
In multivariate analysis, neither the absolute level of platelet 
inhibition in response to clopidogrel nor the response to aspirin 
emerged as an independent predictor of the composite endpoint of 
in-hospital periprocedural myonecrosis, stent thrombosis, non-fatal 
myocardial infarction, stroke and death. The combined endpoint for 
thromboembolic and ischaemic events was predicted by the total 
length of stented segment, GFR <60 ml/min, white blood cell count 
and diabetes. Conversely, a history of previous PCI was associated 
with a risk of fewer events. Recent observations also showed the 
lack of benefit in increasing the dose of clopidogrel among non-
responders12 and the futility of a more potent P2Y12 inhibitor13 to 
reduce the incidence of death from cardiovascular causes, non-fatal 
MI or stent thrombosis at 30 days and six months. However, a trend 
towards fewer cardiovascular events at six months was observed in 
patients with very low PR (PRU <208)14. These findings are con-
sistent with previous observations23 and indicate that clinical and 
procedural characteristics play a more important role than PR in 
predicting early outcomes following PCI in patients with stable 
angina pectoris when treated by aspirin and clopidogrel according 
to current recommendations. However, it has been observed that 
patients with multivessel disease have a higher chance of being 
non-responders than patients with single-vessel disease, and this 
translated into a higher incidence of periprocedural infarctions7. 
Conversely, treatment with GP IIb/IIIa inhibitors in those patients 
significantly improved outcomes23. We therefore cannot exclude 
that platelet reactivity plays an independent role in sicker patients 
with extensive multivessel disease. On the contrary, in patients pre-
senting with an acute coronary syndrome, inflammatory reaction 
and various mechanisms that induce platelet activation are predom-
inant and explain the clinical benefit of a potent platelet inhibition, 
particularly during the first months following PCI. 
Troponin three times greater than normal occurred in 19% of our 
patients undergoing PCI for stable angina. In the meta-analysis of 
Feldman et al24 including series published between 1998 and 2009, 
the rate of troponin elevation following PCI ranged from 26% to 
34%. We may speculate that the lower incidence of myonecrosis 
observed in our study could be attributed to a better inhibition of the 
PR before PCI. Administration of clopidogrel before PCI was fre-
quently omitted in these series or indeed given without adequate 
loading dose. 
Patient, lesion and procedural factors have been associated with 
periprocedural myocardial infarction25,26. In our study, we sorted 
out mechanisms responsible for troponin elevation post PCI in 
194 patients. Procedure-related factors (main vessel or side branch 
occlusion, occlusive dissection, emergency bypass surgery, use of 
rotational atherectomy, etc.) were identified in 54 patients (28%). 
Thromboembolisation and slow flow unexplainable by a proce-
dural cause were noted in 22 patients (11%), while in 118 patients 
no procedure or lesion-related factor could be identified. No differ-
ence was noted between each group with respect to PR. Specifically, 
residual high PR was not identified among patients with slow flow 
post PCI. This suggests that mechanisms other than platelet aggre-
gation or thrombus formation, such as plaque component embolisa-
tion or vasoactive reaction, play an important role in slow flow 
occurring post PCI in stable patients.
Besides periprocedural myonecrosis, the rate of cardiovascular 
events observed in this study was low and similar to that described 
in similar populations of patients undergoing PCI. The frequency of 
major bleeding events was also very low and not associated with 
a high PR. To address the impact of PR on hard clinical and safety 
endpoints in this low-risk population, a large number of patients 
and/or a long-term follow-up observation are therefore required.
Our study evaluated PR to aspirin concomitantly with P2Y12 
reactivity. As expected from previous observations17,27, response to 
aspirin was highly predictable, and resistance to aspirin was noted in 
6.7% of this population. This emphasises the importance of aspirin 
treatment as the cornerstone of antiplatelet therapy. Our results also 
confirmed the wide individual variability in the platelet response to 
clopidogrel. According to point-of-care results, only 49.8% of this 
population of patients with stable coronary artery disease achieved 
an adequate platelet inhibition. The rate of clopidogrel responders 
was 59.3% in the GRAVITAS trial12. Assessment of PR 12 to 
24 hours after PCI may explain the higher rate of response observed 









in this trial. As mentioned before, the unpredictable and poor effi-
cacy of clopidogrel does not affect early outcomes and seems to be 
sufficient to reduce the rate of periprocedural myonecrosis as com-
pared to earlier reports. Overall, resistance to aspirin and clopidogrel 
was recognised in 4% of the population. No clinical or demographic 
data characterised this small subgroup of 34 patients whose outcome 
did not differ from the rest of the population. However, a larger 
series of non-responders to both aspirin and clopidogrel is needed 
before definitive conclusions on the immediate and late conse-
quences of this situation can be drawn.
Numerous studies have shown that individual responsiveness to 
clopidogrel is not uniform. Besides pharmacogenetic factors linked 
to CYP enzymes, cellular and clinical factors may also contribute to 
the reduction of platelet responsiveness to clopidogrel28. The clini-
cal and procedural characteristics of our population assessed 
according to PRU quartiles confirmed that increased platelet reac-
tivity following clopidogrel administration is linked to body mass 
index29. The incidence of diabetes mellitus was significantly more 
frequent from the first to the fourth quartile, in particular the mean 
glycaemia as expressed by HbA1c. We identified other clinical fac-
tors which might influence clopidogrel response. Elevated plasma 
fibrinogen level is increased in relation to increased PRU. 
Fibrinogen level has been found to predict a suboptimal response to 
eptifibatide30, and may also play a role in the level of platelet inhibi-
tion achieved with clopidogrel or other P2Y12 inhibitors. Other 
clinical factors such as advancing age, renal failure or anaemia may 
also play a role and deserve further investigation.
Conclusion
In conclusion, the results of the present study confirm that the level 
of PR immediately before elective PCI in patients pretreated with 
600 mg clopidogrel and 500 mg aspirin is not correlated with early 
clinical outcome after the procedure. Applied to large patient popu-
lations undergoing elective PCI, the absolute level of PR as assessed 
by the VerifyNow point-of-care has little clinical utility in routine 
practice to predict early clinical outcomes. These results do not sup-
port the use of platelet testing in patients undergoing PCI for stable 
coronary artery disease.
Impact on daily practice
Evaluation of platelet reactivity before PCI in patients undergo-
ing angioplasty for stable coronary artery disease, pretreated 
with aspirin and clopidogrel according to guidelines, is futile. 
Reactivity to aspirin and/or clopidogrel, as assessed by point-of-
care VerifyNow, does not predict up to 30-day clinical events, nor 
does it correlate with periprocedural myonecrosis. 
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